$MLNT News
Last published 5y ago
- 5y agoMLNTXLSTravecta Therapeutics Announces Broad Expansion of its Executive, Governance and Scientific Advisory Leadership TeamsPR NewswireSINGAPORE and PRINCETON, N.J., Oct. 27, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier and blood-retinal-barrie
- 5y agoACXPCDTXCRMDITRM+5Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021PR NewswireWASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will presen
- 5y agoCDTXITRMMLNTNBRV+3UTILITY Therapeutics Joins Antimicrobials Working GroupPR NewswireThe Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the...
- 5y agoCDTXITRMMLNTNBRV+3Antimicrobials Working Group Announces Updates to Leadership TeamPR NewswireThe Antimicrobials Working Group (AWG) announced today the appointment of a new Chairperson, Ciara Kennedy, Ph.D., President and Chief Executive...
- 6y agoMLNTDrugmaker Melinta, Co-Founded by Nobel Winner, Files BankruptcyBloombergMelinta Therapeutics Inc., a bio-pharmaceutical company specializing in infectious disease treatment, filed for Chapter 11 bankruptcy in Delaware with plans to continue operating.
- 6y agoMLNTMelinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit FacilityGlobeNewswireMORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and...
- 6y agoMLNTApproval of Orbactivnda (Labeling)FDA Approved DrugsApproval Date: 12/11/2019; Drug Name: Orbactivnda; Company: Melinta Therap; Submission Status: Approval; Submission Classification: Labeling; Application Number: 206334
- 7y agoMLNTMelinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019GlobeNewswireMORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
- 7y agoMLNTMelinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)GlobeNewswire~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ ...
- 7y agoCDTXETTXITRMMLNT+4Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019PR NewswireThe Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving...
- 7y agoMLNTMelinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and DirectorGlobeNewswireMORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
- 7y agoMLNTMelinta Therapeutics Names David Gill as Chairman and Announces CEO Succession PlanGlobeNewswireMORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
- 7y agoMLNTMelinta Therapeutics' (MLNT) CEO John Johnson on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoMLNTMelinta Therapeutics, Inc. (MLNT) CEO John Johnson on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoMLNTMelinta Therapeutics, Inc. (MLNT) Management on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoMLNTMelinta Therapeutics' (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoMDCOMLNTThe Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta TherapeuticsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbacti ...
- 8y agoMDCOMLNTThe Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta TherapeuticsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for $270 million in upfront consideration and guaranteed payments ($215 million of guaranteed cash and $55 million of Melinta common stock), tiered royalty payments of 5% to ...